Targeting the Endothelin A Receptor in IgA Nephropathy

IgA nephropathy is the most common primary glomerulonephritis worldwide and carries a substantial risk of kidney failure. New agency-approved therapies, either specifically for or chronic disease in general, hold out hope mitigating renal deterioration patients with nephropathy. The latest addition to this therapeutic armamentarium targets endothelin-A receptor (ETAR). Activation ETAR on multiple cell types elicits host pathophysiological effects, including vasoconstriction, proliferation, inflammation, apoptosis, fibrosis. Blockade renoprotective experimental models of, reduces proteinuria with, This review discusses evidence supporting use blockade as well addressing potential role class agents amongst current emerging therapies treating disorder.